Data / Drug companies / Gonadotropin Releasing Hormone Receptor Antagonist
Gonadotropin Releasing Hormone Receptor Antagonist drugs: 4 drugs from 12 companies in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Gonadotropin Releasing Hormone Receptor Antagonist is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 14 products in this class from 12 companies, covering 4 drugs by generic name. The main marketing category is generic drugs (ANDA), and the newest product started marketing on January 13, 2026.
The request: Get every company that lists a Gonadotropin Releasing Hormone Receptor Antagonist drug in the FDA NDC directory, with headquarters, website and size. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 12Companies
- 14Products
- 4Drugs by generic name
Drugs in the Gonadotropin Releasing Hormone Receptor Antagonist class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Ganirelix acetate | 10 | 10 |
| Elagolix | 2 | 1 |
| Relugolix | 1 | 1 |
| Relugolix, estradiol hemihydrate, and norethindrone acetate | 1 | 1 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| AbbVie Inc. | 2 | tablet, film coated | New drug applications (NDA) | July 23, 2018 |
| Sumitomo Pharma America, Inc. | 2 | tablet, film coated | New drug applications (NDA) | May 26, 2021 |
| Amphastar Pharmaceuticals, Inc. | 1 | injection | Generic drugs (ANDA) | June 20, 2022 |
| Ferring Pharmaceuticals Inc. | 1 | injection, solution | Generic drugs (ANDA) | February 28, 2022 |
| Fresenius Kabi USA, LLC | 1 | injection | Generic drugs (ANDA) | March 24, 2023 |
| Gland Pharma Limited | 1 | injection, solution | Generic drugs (ANDA) | February 28, 2023 |
| Lupin Pharmaceuticals, Inc. | 1 | injection, solution | Generic drugs (ANDA) | February 14, 2024 |
| Meitheal Pharmaceuticals Inc. | 1 | injection, solution | Generic drugs (ANDA) | June 6, 2022 |
| Mullan Pharmaceutical Inc. | 1 | injection, solution | Generic drugs (ANDA) | January 13, 2026 |
| Organon LLC | 1 | injection, solution | New drug applications (NDA) | June 1, 2021 |
| Qilu Pharmaceutical Co., Ltd. | 1 | injection, solution | Generic drugs (ANDA) | May 15, 2025 |
| Xiromed, LLC | 1 | injection | Generic drugs (ANDA) | April 1, 2024 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 7 | 50% |
| Tablet, film coated | 4 | 28.6% |
| Injection | 3 | 21.4% |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.